Clevidipine Versus Nicardipine in Hypertensive Crisis: Three Studies, Very Low Certainty
This small meta-analysis pools one randomized trial and two cohort studies to compare two intravenous dihydropyridine calcium channel blockers, giving cardiology pharmacists a first synthesis of comparative data outside neurocritical care.
📅 Journal publication: Jul 24, 2026·Last updated: Nov 2, 2026
Clevidipine and nicardipine equally effective in hypertensive crises management.
Clevidipine and nicardipine are both used for hypertensive crises, yet their comparative efficacy and safety are not well established. Clevidipine had comparable efficacy to nicardipine in target blood pressure reduction with lower odds of over-reduction and less medication volume required. The findings suggest clevidipine may have advantages but are based on very low-certainty evidence, limiting their immediate applicability. Clevidipine and nicardipine show similar efficacy, clevidipine possibly safer in some respects, but evidence is weak.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Abid H, Shah SMA, Rashid AZ, Tasawar B, Adnan R, Memon S, Lohano G, Jawad M, Vazaym M, Junaid M
Citation:Abid H, Shah SMA, Rashid AZ, et al. Clevidipine vs. nicardipine in hypertensive crisis: a systematic review and meta-analysis. BMC cardiovascular disorders. 2026;26(1). doi:10.1186/s12872-026-06345-z